Ann: Paradigm Corporate Update - May 2019, page-11

I imagine the company had already completed their deal for a CR with the Insto’s well before the Secondary endpoints Ann however I wonder how the price would have reacted to the Ann without the CR until a bit later?
Foolishly perhaps, I was thinking the price could have continued to surge upwards towards $3 on the Secondary Ann only and then do the CR which is perhaps less kind to current investors including 51Cap.
Of course, hindsight and that though I assume it was also important to get the Insto’s in as cheap as possible however the share price now appears stuck and without a significant catalyst to stimulate further appreciation could it be holding fast at these levels?
Other stimuli may be that the Insto’s did not receive enough shares for their portfolios and will put upwards pressure on price as they accumulate?
Ross River report is also something to look forward to IF successful and later Phase3 results.
Further, does anyone know the full scope of the Phase3 trial and particularly what criteria are required for the trial to be deemed a success?